AI 创业公司融资日历

1819 家公司 1840 轮融资 306 家已接到招聘板 全部在招职位 →

💡 刚融资 = 正在扩招。 创业公司拿到钱第一件事就是扩团队——先到先得。看到心仪的公司刚融资,点"→ 在招岗位",趁招聘高峰投。

轮次 全部 Series ASeedSeries BSeries CSeries DPre-SeedGrowthSeries EDebtSeries FSeries G+RoundPrivate Equity
领域 全部 FinTechAI InfrastructureEnterprise SaaSDeveloper ToolsHealthcareHardware & RoboticsConsumerCybersecurityMarketing & AdTechData & AnalyticsPropTech & ConstructionInfrastructureClimate TechHR & Workforce
筛选 ✅ 只看正在招人的 ≥ $50M 2026 年 ✕ 清除全部

当前显示 20 轮 · 合计 $3.3B · 其中 6 家正在招人

2026 年 7月1 轮

Chai Discovery Series C $400M Biotech 累计 $625M
AI-based molecular interactions platform for drug discovery performing state-of-the-art structure prediction and antibody design

2026 年 6月3 轮

Cellares Series D $327M Biotech 累计 $682M
Cellares is an integrated development and manufacturing organization (IDMO) for cell therapies, using automation and industrial-scale manufacturing sy…
Collate Series B $95M Biotech 累计 $125M
AI document generation platform for life sciences that automates regulatory paperwork for diagnostic, medical device, and drug development companies. …
NewLimit Series C $435M Biotech 累计 $760M
NewLimit develops epigenetic reprogramming medicines to restore youthful cellular function and treat diseases with large unmet needs. Co-founded by Br…

2026 年 3月1 轮

Science Series C $230M Biotech 累计 $490M
Science Corporation is a neural engineering company developing brain-computer interface (BCI) technology to restore and enhance human vision. The comp…
未接到招聘板 待核实

2026 年 2月5 轮

Loyal Series C $100M Biotech 累计 $250M
Loyal is a clinical-stage veterinary medicine company developing longevity drugs to help dogs live longer, healthier lives. They are the first company…
未接到招聘板 待核实
Angitia Series D $130M Biotech 累计 $420M
Angitia is a biotechnology company developing novel therapies for endocrine and metabolic diseases, including rare disease programs.
未接到招聘板 待核实
Osmo Series B $70M Biotech 累计 $130M
Osmo uses AI-powered olfactory intelligence to digitize and generate custom scent formulas, building the world's first AI-powered fragrance house with…
Third Arc Bio Series A $52M Biotech 累计 $217M
Third Arc Bio is an immunology and inflammation-focused biotechnology company developing targeted immune therapeutics across oncology and inflammatory…
未接到招聘板 待核实
Colossal Biosciences Series C $60M Biotech 累计 $615M
Colossal Biosciences is a genetic engineering and de-extinction company using CRISPR technology to restore extinct species like the woolly mammoth and…

2026 年 1月1 轮

Breakthru Medicine Series A $60M Biotech
Breakthru Medicine is a biotech company developing novel oncology therapies, with a focus on first-in-class radioconjugate treatment approaches for ca…
未接到招聘板 待核实

2025 年 12月2 轮

Edison Scientific Seed $70M Biotech
Edison Scientific builds and deploys autonomous AI scientist agents to accelerate research and drug development. Its flagship platform, Kosmos, runs h…
未接到招聘板 待核实
Medra Series A $52M Biotech 累计 $63M
Medra develops autonomous AI-powered robotic scientists that run and refine laboratory experiments end-to-end, interfacing with standard lab tools to …
未接到招聘板 待核实

2025 年 11月1 轮

Profluent Series B $106M Biotech 累计 $150M
AI-first protein design company using deep generative models to create novel, functional proteins for applications in biomedicine, agriculture, and ge…
未接到招聘板 待核实

2025 年 10月2 轮

Lila Sciences Series A $350M Biotech 累计 $550M
A platform using artificial intelligence to support research in life sciences, chemical sciences, and materials sciences through autonomous AI labs bu…
未接到招聘板 待核实
NILO Therapeutics Series A $101M Biotech
Nilo Therapeutics is a New York-based biotech developing a new class of medicines that harness brain-body neural circuits to restore immune homeostasi…
未接到招聘板 待核实

2025 年 9月2 轮

Until Series A $58M Biotech 累计 $106M
Until Labs develops reversible cryopreservation technology to pause biological time, starting with organ-scale preservation to extend the viability of…
未接到招聘板 待核实
Enveda Series D $150M Biotech 累计 $517M
AI-powered drug discovery platform advancing nature-inspired therapeutics from plants and natural products into clinical development.
未接到招聘板 待核实

2024 年 11月1 轮

Cradle Series B $73M Biotech 累计 $103M
Cradle builds an AI-powered protein engineering platform that helps biotech teams design and optimize proteins faster across discovery workflows.
未接到招聘板 待核实

2024 年 6月1 轮

Formation Bio Series D $372M Biotech 累计 $608M
Formation Bio (formerly TrialSpark) is an AI-native pharmaceutical company that acquires and develops clinical-stage drugs using a technology platform…
未接到招聘板 待核实